

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/129418/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Jeffries, Aaron R., Maroofian, Reza, Salter, Claire G., Chioza, Barry A., Cross, Harold E., Patton, Michael A., Dempster, Emma, Temple, I. Karen, Mackay, Deborah J.G., Rezwan, Faisal I., Aksglaede, Lise, Baralle, Diana, Dabir, Tabib, Hunter, Matthew F., Kamath, Arveen, Kumar, Ajith, Newbury-Ecob, Ruth, Selicorni, Angelo, Springer, Amanda, Van Maldergem, Lionel, Varghese, Vinod, Yachelevich, Naomi, Tatton-Brown, Katrina, Mill, Jonathan, Crosby, Andrew H. and Baple, Emma L. 2019. Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging. *Genome Research* 29 (7) , pp. 1057-1066. 10.1101/gr.243584.118

Publishers page: <http://dx.doi.org/10.1101/gr.243584.118>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging

Aaron R Jeffries¹, Reza Maroofian², Claire G. Salter^{1,3,4}, Barry A. Chioza¹, Harold E. Cross⁵, Michael A. Patton^{1,2}, Emma Dempster¹, I. Karen Temple^{3,4}, Deborah Mackay³, Faisal I. Rezwan³, Lise Aksglæde⁶, Diana Baralle³, Tabib Dabir⁷, Matthew Frank Hunter⁸, Arveen Kamath⁹, Ajith Kumar¹⁰, Ruth Newbury-Ecob¹¹, Angelo Selicorni¹², Amanda Springer¹³, Lionel van Maldergem¹⁴, Vinod Varghese⁹, Naomi Yachelevich¹⁵, Katrina Tatton-Brown^{16,17}, Jonathan Mill^{1*}, Andrew H. Crosby^{1*} and Emma Baple^{1,18*}

1. University of Exeter Medical School, RILD Wellcome Wolfson Centre, Royal Devon & Exeter NHS Foundation Trust, Barrack Road, Exeter, EX2 5DW, UK
2. Genetics Research Centre, Molecular and Clinical Sciences Institute, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK
3. Human Genetics and Genomic Medicine, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK
4. Wessex Clinical Genetics Service, Princess Anne Hospital, Coxford Road, Southampton, SO16 5YA, UK
5. Department of Ophthalmology and Vision Science, University of Arizona School of Medicine, 655 N. Alvernon Way, Tucson, Arizona, USA
6. Department of Clinical Medicine, University of Copenhagen, Denmark
7. Northern Ireland Regional Genetics Centre, Clinical Genetics Service, Belfast City Hospital, Belfast, UK
8. Monash Genetics, Monash Health, Clayton, Victoria, Australia
9. Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK
10. North East Thames Regional Genetics Service and Department of Clinical Genetics, Great Ormond Street Hospital, London, UK

11. University Hospitals Bristol NHS Trust / University of Bristol, Bristol, UK
12. UOC Pediatria ASST Laraina, Como, Italy
13. Department of Paediatrics, Monash University, Clayton, Victoria, Australia
14. Centre de Génétique Humaine and Integrative and Cognitive Neuroscience Research
Unit EA481, Besançon, Besançon, France
15. Clinical Genetics Services, New York University Hospitals Center, New York University,
New York, NY, USA
16. Division of Genetics and Epidemiology, Institute of Cancer Research, 15 Cotswold
Road, London SM2 5NG, UK
17. South West Thames Regional Genetics Service, St George's University Hospitals NHS
Foundation Trust, London SW17 0QT, UK
18. Peninsula Clinical Genetics Service, Royal Devon & Exeter Hospital, Gladstone Road,
Exeter, EX1 2ED, UK

*Correspondence should be addressed to:

Co-corresponding author email: e.baple@exeter.ac.uk (ELB)

Co-corresponding author email: a.h.crosby@exeter.ac.uk (AHC)

Co-corresponding author email: j.mill@exeter.ac.uk (JM)

Running Title: Epigenetic aging abnormalities in growth disorders

Key Words: Epigenetic aging, DNA methylation, Tatton-Brown-Rahman syndrome, DNMT3A,
Cancer

Abstract

Germline mutations in fundamental epigenetic regulatory molecules including DNA methyltransferase 3A (*DNMT3A*) are commonly associated with growth disorders, whereas somatic mutations are often associated with malignancy. We profiled genome-wide DNA methylation patterns in *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers in a large Amish sibship with Tatton-Brown-Rahman syndrome (TBRS), their mosaic father and 15 TBRS patients with distinct pathogenic de novo *DNMT3A* variants. This defined widespread DNA hypomethylation at specific genomic sites enriched at locations annotated to genes involved in morphogenesis, development, differentiation, and malignancy predisposition pathways. TBRS patients also displayed highly accelerated DNA methylation aging. These findings were most marked in a carrier of the AML associated driver mutation p.Arg882Cys. Our studies additionally defined phenotype related accelerated and decelerated epigenetic aging in two histone methyltransferase disorders; NSD1 Sotos syndrome overgrowth disorder and KMT2D Kabuki syndrome growth impairment. Together, our findings provide fundamentally new insights into aberrant epigenetic mechanisms, the role of epigenetic machinery maintenance and determinants of biological aging in these growth disorders.

Introduction

DNA methylation is an essential epigenetic process involving the addition of a methyl group to cytosine. It is known to play a role in many important genomic regulatory processes, including X Chromosome inactivation, genomic imprinting and the repression of tumor suppressor genes in cancer, mediating transcriptional regulation as well as genomic stability (Jones 2012). Three catalytically active DNA methyltransferases (DNMTs) are involved in the methylation of cytosine: *DNMT1*, which is mainly responsible for the maintenance of DNA methylation over replication and *DNMT3A* and *DNMT3B*, which generally perform *de novo* methylation of either unmethylated or hemimethylated DNA. An absence of these enzymes in mice results in embryonic (*DNMT1* and *3B*) or postnatal (*DNMT3A*) lethality (Okano et al. 1999), confirming their essential roles in development. In line with knockout mouse models, pathogenic variants affecting the chromatin binding domains of *DNMT1* have been shown to cause two separate progressive autosomal dominant adult-onset neurologic disorders (Klein et al. 2011). Biallelic pathogenic variants in *DNMT3B* have been associated with immunodeficiency, centromere instability and facial anomalies (ICF) syndrome (Jiang et al. 2005). To date, *DNMT3A* has been linked to a number of physiological functions, including cellular differentiation, malignant disease, cardiac disease, learning and memory formation. Somatically acquired pathogenic variants in *DNMT3A* are associated with over 20% of acute myeloid leukemia (AML) cases, whilst heterozygous germline pathogenic loss of function variants have been found to underlie Tatton-Brown-Rahman syndrome (TBRS; also known as DNMT3A-overgrowth syndrome, OMIM: 615879) (Challen et al. 2011; Tatton-Brown et al. 2014). TBRS is characterized by increased growth, intellectual disability (ID) and dysmorphic facial features. More recently, heterozygous gain of function *DNMT3A* missense variants affecting the DNMT3A PWWP domain have been shown to cause microcephalic dwarfism and hypermethylation of Polycomb-regulated regions (Heyn et al. 2019).

There is an emerging group of epigenetic regulatory molecule-associated human growth disorders where the underlying molecular defect is a disruption to the DNA methylation and histone machinery. There are now over 40 disorders identified within this group, which can be further subgrouped into diseases resulting from disruption of the ‘writers’, ‘readers’ and ‘erasers’ of epigenetic modifications (Bjornsson 2015). Example disorders in each group include Kabuki, Sotos and Weaver syndromes (‘writers’), Smith-Magenis, Rett and Bohring-Optiz syndromes (‘readers’), and Wilson-Turner and Cleas-Hensen syndromes (‘erasers’). The final subgroup occurs due to disruption of chromatin remodellers, with example resulting disorders including CHARGE and Floating Harbour syndromes. Neurological and cognitive impairment are common features of these conditions, suggesting that precise epigenetic regulation may be critical for neuronal homeostasis. However, a true understanding of the pathogenic mechanism underlying these conditions remains poorly understood.

In the current study, we investigated the methylomic consequences of a *DNMT3A* pathogenic variant (NC_000002.12:g.25240312C>T; NM_022552.4:c.2312G>A; p.Arg771Gln) in a large Amish family comprising four individuals affected with TBRS arising due to a mosaic pathogenic *DNMT3A* variant in their father (Xin et al. 2017). The occurrence of multiple affected and unaffected individuals in the same sibship, together with the combined genetic and environmental homogeneity of the Amish, permitted an in-depth investigation of the genome-wide patterns of DNA methylation associated with pathogenic variation in *DNMT3A*. We subsequently extended our analyses to other (non-Amish) TBRS patients harbouring distinct pathogenic *de novo* *DNMT3A* variants, as well other methyltransferase associated overgrowth and growth deficiency syndromes, defining altered epigenetic profiles as common key themes of these growth disorders.

Results

Reduced DNA methylation at key sites involved in morphogenesis, development and differentiation in TBR1 patients

DNMT3A encodes a DNA methyltransferase with both *de novo* and maintenance activity (Okano et al. 1999; Chen et al. 2003). We first looked for global changes in DNA methylation in whole blood obtained from *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers, using the methylation-sensitive restriction enzyme based LUMA assay (Karimi et al. 2006) to quantify DNA methylation across GC rich regions of the genome, finding no evidence for altered global DNA methylation (LUMA: mean *DNMT3A* c.2312G>A carriers = 0.274, wildtype = 0.256, *t*-test *p*-value = 0.728). We next quantified DNA methylation at 414,172 autosomal sites across the genome using the Illumina 450k array. Globally, a subtle decrease in mean DNA methylation was noted in available age/sex matched *DNMT3A* heterozygous c.2312G>A; p.(Arg771Gln) individuals compared to their matched unaffected sib samples although this was not statistically significant (Wilcoxon Rank Sum test *p*-values for two matched pairs=0.24 and 0.14, Supplemental Fig S1). In contrast, an analysis of site-specific DNA methylation differences in *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers (including the mosaic father) vs wildtype individuals in the Amish pedigree identified 2,606 differentially methylated positions (DMPs) (Benjamini-Hochberg FDR < 0.05) (Fig. 1A,B and Supplemental Table S1), of which 1,776 DMPs were characterized by a >10% change in DNA methylation. Supplemental Fig S2 also highlights DNA methylation levels at these DMPs across all carriers and control individuals profiled in this study. Technical validation of Illumina 450K array data was performed using bisulfite pyrosequencing for three top-ranking DMPs, confirming significant differences in *DNMT3A* c.2312G>A carriers at each of the tested loci (Supplemental Fig S3).

The DMPs identified were highly enriched for sites characterized by reduced DNA methylation in *DNMT3A* c.2312G>A; p.(Arg771Gln) heterozygotes ($n = 2,576$ DMPs, 98.85%, sign-test p -value $< 2.2 \times 10^{-16}$). Although there were no statistically significant differences between DNA methylation based blood cell composition estimates derived from our data (Supplemental Table S2), we examined the extent to which the identified DMPs were potentially influenced by cell-type differences between *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers and wildtype family members. There was a highly significant correlation ($r = 0.876$, p -value $< 2.2 \times 10^{-16}$, Supplemental Fig S4) in effect sizes at the 2,606 DMPs between models including and excluding cell-types as covariates, indicating that the observed patterns of differential DNA methylation are not strongly influenced by cell-type variation. We used DMRcate (Peters et al. 2015) to identify spatially correlated regions of differential DNA methylation significantly associated with the *DNMT3A* c.2312G>A; p.(Arg771Gln) variant, identifying 388 autosomal differentially methylated regions (DMRs) (example DMR shown in Supplemental Fig S5), all characterized by hypomethylation in *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers apart from one 739bp DMR which showed increased DNA methylation (Supplemental Table S3). The mean size of the identified DMRs was 625bp (range = 6 to 5,522bp), spanning an average of 6 probes (Supplemental Fig S6).

We next investigated whether *DNMT3A* p.(Arg771Gln)-associated DMPs are enriched in specific genic locations (see Methods). We found a modest enrichment of DMPs in regions 1500bp or more upstream of the transcriptional start site (Chi-Squared Yates corrected p -value=0.047) and more prominent enrichment in intergenic regions (Chi-Squared Yates corrected p -value= 1.54×10^{-14}) (Supplemental Fig S7). DMPs were also significantly enriched in CpG Island shore regions (Chi-Squared Yates corrected p -value= 8×10^{-30}) (Supplemental Fig S7). We also examined DMP occurrence in experimentally determined cancer and reprogramming specific DMR locations (Doi et al. 2009), finding a 2.4 fold and 4.7 fold

overrepresentation (Chi-Squared Yates corrected p-value= 4.24×10^{-6} and Chi-Squared Yates corrected p-value $<1.3 \times 10^{-41}$ respectively), as well as predicted enhancer elements which showed a 1.4 fold overrepresentation (Chi-Squared Yates corrected p-value= 7.57×10^{-16}). We then undertook Gene Ontology analysis, accounting for the background distribution of probes on the Illumina 450K array, to functionally annotate the DNA methylation differences observed in the *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers. The 2,606 DMPs identified in this study showed a significant overrepresentation in functional pathways related to morphogenesis, development and differentiation (top hit: GO:0007275 - multicellular organism development, contains 474 genes associated with DMPs, FDR Q-value= 3.7×10^{-7}) (Fig. 1C, Supplemental Table S4). We also performed a functional overlap analysis to identify cell- or tissue-specific chromatin signals associated with these DMPs using eFORGE (Breeze et al. 2016). Significant overlap (FDR Q-value < 0.01) was found with DNase I sensitivity hotspots, most apparent with pluripotent cells in ENCODE (The Encode Project Consortium 2012; Davis et al. 2018) and fetal tissues within the NIH Roadmap Epigenomics Consortium dataset (Roadmap Epigenomics Consortium 2015) (Supplemental Data S1). Chromatin states from the NIH Roadmap Epigenomics Consortium dataset show an enrichment of DMPs in regions defined as active transcriptional start sites in brain tissue and embryonic stem cells. Of particular interest, given the established importance of *DNMT3A* during embryonic development, eFORGE analysis of blood cell types highlighted an enrichment of DMPs in regions characterized by repressed polycomb and enhancer activity.

To provide additional evidence to support the notion that *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers exhibit disruption to developmental pathways, we used the Genomic Regions Enrichment of Annotation Tool (GREAT) (McLean et al. 2010) to explore functional pathways enriched in genes annotated to *DNMT3A* c.2312G>A; p.(Arg771Gln)-associated DMRs. This revealed a significant effect on genes implicated in developmental pathways (1st ranked GO

Biological Process = Skeletal System Development, fold enrichment = 2.5, binomial FDR Q-value= 9.22×10^{-7}), with a specific enrichment for Homeobox protein domain encoding genes (InterPro) (fold enrichment=239.59, binomial FDR Q-value= 4.15×10^{-23}), fundamental for normal developmental processes. An enrichment for malignancy terms was also noted, (from the Molecular Signatures Database (Liberzon et al. 2011)) (1st ranked term = Genes with promoters occupied by PML-RARA fusion protein in acute promyelocytic leukemia (APL) cells NB4 and two APL primary blasts, based on ChIP-seq data, fold enrichment=3.14, binomial FDR Q-value= 6.18×10^{-7}) (see Supplemental Data S2).

To establish whether these differentially methylated positions are a consistent feature of TBRS, we profiled a further 15 non-Amish patients carrying distinct previously published *DNMT3A* pathogenic variants (Fig. 2 and Table 1) using the Illumina EPIC DNA methylation array. Examination of the originally differentially methylated positions identified in *DNMT3A* c.2312G>A; p.(Arg771Gln) mutation carriers revealed that the majority of differentially methylated positions were common to all of the TBRS patients regardless of the underlying causative *DNMT3A* variant (Fig. 1D), with a Pearson correlation coefficient of 0.6620 (p-value $<2.2 \times 10^{-16}$) for effect sizes across all DMPs. Each variant showed some heterogeneity in effect size (Fig. 1E), with *DNMT3A* c.2644C>T p.(Arg882Cys) associated with the greatest overall changes in DNA methylation. These data lead us to conclude that TBRS patients show loss of methylation at sites annotated to key genes involved in development and growth pathways, mirroring the well-characterized overgrowth and neurocognitive features that characterize this disorder.

DNMT3A mutations are associated with highly accelerated epigenetic aging, particularly the cardinal AML driver mutation p.Arg882Cys

DNA methylation at a specific set of CpG sites, representing a so-called “epigenetic clock”, has been shown to be strongly correlated with chronological age (Horvath 2013). Deviations from chronological age have been associated with several measures of accelerated biological aging and age-related phenotypes (Johnson et al. 2012; Levine et al. 2015; Marioni et al. 2015; Chen et al. 2016). We investigated the DNA methylation age of *DNMT3A* c.2312G>A p.(Arg771Gln) carriers using the DNA age calculator (<http://dnamage.genetics.ucla.edu/>) (Horvath 2013) finding that *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers show evidence for highly-accelerated aging - an increase of ~40% beyond their chronological age - when compared to wildtype family members (ANCOVA p-value=0.004) (Fig. 3A). Only 1 of 353 probes used in the epigenetic clock (Horvath 2013) overlapped with the DMPs significantly associated with the *DNMT3A* c.2312G>A; p.(Arg771Gln) pathogenic variant, leading us to conclude that this finding represented a true acceleration of epigenetic age. Furthermore, when compared to an extensive number (322) of wild-type control samples profiled in a previous study from our group (Hannon et al. 2016), *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers were consistent outliers for epigenetic age suggesting their profiles fall outside the normal distribution of variance observed in the general population (Supplemental Fig S8). Consistent with this, the mosaic Amish father was found to have intermediate level of epigenetic age acceleration, with a 23% increase over his chronological age. This age acceleration was a cumulative process as indicated by the increased slope of *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers vs wildtype. Epigenetic age could therefore be predicted by the linear regression model as follows: epigenetic age = 4.81 + 1.405 × chronological age. The cumulative increase of epigenetic age relative to chronological age is also notable when compared to a recent meta-analysis of longitudinal cohort data which

shows the trajectory of epigenetic age in different populations progresses at a slightly slower rate when compared to increasing chronological age (Marioni et al. 2018).

We next looked for evidence of elevated epigenetic aging in the 15 additional *de novo* *DNMT3A* pathogenic variant carriers with TBRS overgrowth syndrome. All TBRS patients showed accelerated epigenetic aging, although the position and type of each variant results in differing degrees of accelerated epigenetic aging (Table 1). The greatest rate of epigenetic age acceleration (>800%) was observed in association with the germline p.(Arg882Cys) substitution, somatic mutation of *DNMT3A* Arg882 being the most commonly associated with acute myeloid leukemia (AML).

Altered epigenetic aging in methyltransferase-associated human growth disorders

To determine whether altered epigenetic aging is a characteristic of other growth disorders associated with disruption of epigenetic regulatory molecules, we extended our study using publicly-available Illumina 450K DNA methylation data. We first analysed the data from individuals with Sotos syndrome, a congenital overgrowth syndrome which results from mutation of the epigenetic modifier *NSD1* (Supplemental Table S5), a lysine histone methyltransferase, (Kurotaki et al. 2002; Qiao et al. 2011). Consistent with *DNMT3A* pathogenic variant carriers, these individuals are characterized by an epigenetic age acceleration of ~40% (linear regression model $R^2=0.869$, $p\text{-value}=6.4\times10^{-9}$) (Fig. 3B,3D). We then examined data from individuals with Kabuki syndrome patients with pathogenic variants in the *KMT2D* gene (Supplemental Table S6), which also encodes a lysine histone methyltransferase, (Ng et al. 2010; Butcher et al. 2017). Kabuki syndrome is a multisystem disorder with patients typically presenting with post-natal growth deficiency (rather than overgrowth), characteristic facial features, intellectual disability and other variable features. Although there is more heterogeneity in epigenetic age when compared with the *NSD1* mutation carriers there was a significant

reduction in epigenetic age of approximately 40% seen across these individuals (linear regression model $R^2=0.418$, p-value=0.023) (Fig. 3C,3D).

Discussion

To date, 78 individuals have been described with the overgrowth condition TBRS. Within this group a wide variety of germline *DNMT3A* pathogenic variants have been reported including 33 missense, eight stop-gain, seven frameshift, two splice site variants, two in-frame and five whole-gene deletions (including a set of identical twins) (Tatton-Brown et al. 2014; Okamoto et al. 2016; Tlemsani et al. 2016; Hollink et al. 2017; Kosaki et al. 2017; Lemire et al. 2017; Shen et al. 2017; Spencer et al. 2017; Tatton-Brown et al. 2017; Xin et al. 2017; Tatton-Brown et al. 2018). Clinically, the predominant features of TBRS are overgrowth, a characteristic facial gestalt and neurocognitive impairment. These features show phenotypic overlap with conditions associated with germline pathogenic variants in other epigenetic regulatory genes, including Sotos and Weaver syndrome caused by variants in *NSD1* and *EZH2* histone methyltransferases respectively (Tatton-Brown et al. 2017). These genes encode essential epigenetic regulatory proteins, with a dual somatic/germline role in the pathogenesis of haematological malignancies and overgrowth syndromes with variable degrees of intellectual impairment (Tatton-Brown et al. 2014).

The majority of *DNMT3A* pathogenic variants in TBRS have been found to be *de novo*, with five individuals inheriting the pathogenic variant from two mosaic parents (Tlemsani et al. 2016; Xin et al. 2017) and two individuals inheriting the pathogenic variant from their affected father (Lemire et al. 2017). Extensive studies of the role of *DNMT3A* in haematopoietic stem cell (HSC) differentiation are also reported, including the regular occurrence of somatic *DNMT3A* variants in patients with acute myeloid leukaemia (AML). The most common somatic pathogenic variant reported in patients with AML affects the amino acid residue Arg882. To date, pathogenic variation at this residue has been described in the germline of 12 TBRS patients, five with p.(Arg882His) and seven with p.(Arg882Cys) (Tlemsani et al. 2016; Hollink et al. 2017; Kosaki et al. 2017; Shen et al. 2017; Spencer et al. 2017; Tatton-Brown et al. 2018). Despite

these studies, the underlying biological mechanism and outcomes of gene mutation in TBRS, and the potential risks of haematological malignancy, remain largely unclear.

Here we investigated variation in DNA methylation associated with a germline heterozygous *DNMT3A* missense pathogenic variant c.2312G>A; p.(Arg771Gln), affecting the catalytic MTase domain, in a large Amish family comprising four children with TBRS, unaffected siblings, and their mosaic father who displayed an intermediate clinical phenotype (Xin et al. 2017). Affected individuals were characterized by widespread hypomethylation, with DMPs enriched in the vicinity of genes/regulatory regions associated with growth and development, tissue morphogenesis and differentiation. The magnitude of hypomethylation typically exceeded 10%, a level often considered to show biological significance (Leenen et al. 2016). The accelerated epigenetic age observed did not appear to be driven by overlap of the *DNMT3A* c.2312G>A; p.(Arg771Gln) variant associated DMPs with the probes that comprise the epigenetic clock as shown by overlap with only 1 out of the 353 probes used in the epigenetic age estimation (Horvath 2013). Although the relevance of blood cells to understanding the aetiology of TBRS is not yet known, we hypothesize that our findings will be generalizable across cell types given the ubiquitous developmental expression of *DNMT3A* and given that many age associated differentially methylated positions are shared across different cell types (Zhu et al. 2018). Nevertheless, it would still be prudent to undertake epigenetic age assessment of other tissues from TBRS patients to determine whether epigenetic age truly is accelerated across all cell types or a finding that is limited to blood.

While dysregulation of growth control has been linked to numerous developmental disorders and malignancy, the specific molecular basis of this relationship is not fully understood. The assessment of DMPs associated with *DNMT3A* c.2312G>A; p.(Arg771Gln) variant TBRS individuals showed associations of pluripotent and fetal DNase I sensitivity hotspots, and also brain and embryonic stem cell associated chromatin sites according to The Encode Project

Consortium and Epigenomic Roadmap Consortium datasets (Breeze et al. 2016). Similarly, functional annotation based on Gene Ontology terms showed an overrepresentation morphogenesis, development and differentiation. DNMT3A loss of function has previously been reported to result in upregulated multipotency genes and impaired differentiation of neural and hematopoietic stem cells (Wu et al. 2010; Challen et al. 2011; Jeong et al. 2018) compared to a gain of function DNMT3A variant which may increase cellular differentiation (Heyn et al. 2019). It is therefore conceivable that the DNMT3A loss of function variants associated TBRS may promote increased proliferation of stem/progenitor cell pool, resulting in increased cell numbers during organ morphogenesis and clinical overgrowth.

Our finding of altered epigenetic outcomes in TBRS prompted us to consider similar investigations in other growth disorders associated with epigenetic dysfunction; Sotos syndrome, a neurodevelopmental disorder with features overlapping TBRS and associated with overgrowth in childhood due to histone methyltransferase *NSD1* gene alterations, and Kabuki syndrome, a distinct neurodevelopmental disorder associated with poor growth and histone methyltransferase *KMT2D* gene alterations. This work defined clear aberrations in epigenetic aging appropriate to the specific nature of each condition. In both overgrowth conditions, TBRS and Sotos syndrome, we identified accelerated epigenetic aging as measured by the DNA methylation age calculator (Horvath 2013). Conversely patients with Kabuki syndrome clinically characterized by poor growth, displayed decelerated epigenetic age. Epigenetic age has been strongly correlated with chronological age in unaffected individuals in previous studies of a variety of tissue types (Hannum et al. 2013; Horvath 2013). The observation of accelerated epigenetic aging in both TBRS and Sotos syndrome potentially results from reduced methyltransferase activity, in addition to increased cell turnover associated with the overgrowth seen with these disorders, with the converse being the case for Kabuki syndrome. Accelerated epigenetic aging has been associated with age-related clinical characteristics and mortality in

epidemiological studies. For example, accelerated epigenetic age in lymphocytes correlates with reduced physical and cognitive function in the elderly, and increased overall mortality independent of other variables such as BMI, sex and smoking status (Marioni et al. 2015; Chen et al. 2016). The molecular basis of TBRS has only been determined relatively recently and as such, most of the affected individuals reported are children and young adults. There is therefore still only very limited data available relating to the progression and prognosis of this disorder, meaning that it is not yet possible to determine whether there might any clinical evidence of multi-morbidity indicative of premature aging or a reduction in average life span in TBRS. Further long-term natural history studies of TBRS patients will be extremely helpful for determining the clinical implications of the epigenetic age acceleration observed as a feature of this disorder.

Accelerated epigenetic age has previously been reported in association with specific diseases such as Huntington's disease (+ 3.4 years) (Horvath et al. 2016), Down's syndrome (+ 6.6 years) (Horvath et al. 2015) and Werner's syndrome (+ 6.4 years) (Maierhofer et al. 2017). The accelerated epigenetic aging described in association with these disorders is an average increase in epigenetic age which is relatively consistent throughout lifespan. A distinguishing feature of carriers of the Amish *DNMT3A* c.2312G>A; p.(Arg771Gln) variant is the year on year or cumulative increase of accelerated epigenetic aging over life time course, i.e. a true acceleration of epigenetic aging. While these studies were not possible for the other *DNMT3A* variants, this may be indicative of a similar effect on cumulative epigenetic age acceleration over life course in TBRS. It is also noted that the gene encoding DNMT3L is located on Chromosome 21, given the previous report of an average DNA methylation age acceleration of 6.6 years in blood and brain tissue in individuals with Down syndrome (Horvath et al. 2015) and the role of DNMT3L in stimulating DNMT3A *de novo* methylation, further investigations are needed to explore the potential relevance of this intriguing observation.

There are currently only four reported cases of an AML tumour carrying the DNMT3A p.Arg771Gln mutation which was present as a germline mutation in the Amish TBRS patients in our study. Biochemical measurements of DNMT3A enzyme show that mutations at both the Arg771 and Arg882 residues result in reduced methyltransferase activity, with a greater degree of reduction resulting from Arg882 variants compared to Arg771 variants (2.4 fold difference) (Holz-Schietinger et al. 2012). Given this reduced methyltransferase activity, we may expect to observe more pronounced changes in DNA methylation in patients with germline variants affecting Arg882 when compared to variants affecting other amino acid residues such as Arg771. Our data reflected this notion, with alteration Arg882 displaying markedly greater methylation changes compared to the other DNMT3A mutations investigated in this study. Currently available literature suggests that the risk of haematological malignancy in TBRS individuals may vary depending on the specific pathogenic variant underlying their condition (Hollink et al. 2017). The significantly advanced epigenetic age that we observed in association with p.Arg882Cys may explain why haematological malignancy has to date only been reported in two TBRS patients, one harbouring this germline variant and the second the p.Tyr735Ser variant, the latter not being assessed in this study (Hollink et al. 2017; Tatton-Brown et al. 2018).

In summary, our findings identify widespread DNA hypomethylation in genes involved in morphogenesis, development, differentiation and malignancy in TBRS patients. TBRS patients also displayed highly accelerated DNA methylation aging. Our studies additionally defined phenotype related altered epigenetic aging in two histone methyltransferase disorders; NSD1 Sotos syndrome overgrowth disorder and KMT2D Kabuki syndrome growth impairment. Taken together, these findings provide important new insights into the role of DNMT3A during development, and of relevance to haematological malignancy, and define perturbation to

epigenetic machinery and biological ageing as common themes in overgrowth and growth deficiency syndromes.

Methods

Genetic and Clinical Studies

The phenotypic features of the four affected siblings (3 females and 1 male, aged 10-25 years; Fig. 1A individuals III:3, III:5, III:7 and III:13) include: macrocephaly, tall stature, obesity, hypotonia, mild to moderate intellectual disability, behavioural problems, and a distinctive facial appearance. Whole genome SNP genotyping and exome sequencing of DNA samples taken with informed consent under regionally-approved protocols excluded mutations in known genes, or candidate new genes, associated with neurodevelopmental disorders. Subsequent studies defined a heterozygous c.2312G>A substitution in *DNMT3A*, resulting in a p.(Arg771Gln) substitution associated with TBRS as the cause of the condition, and full clinical details are described in Xin et al 2017 (Xin et al. 2017). Further testing revealed mosaicism for the *DNMT3A* c.2312G>A variant in the father, and Xin et al. (Xin et al. 2017), demonstrated pathogenic variant load varied in different tissue types.

DNA Methylation Profiling

Genomic DNA from blood was sodium bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo Research, Irvine, CA, USA) and DNA methylation quantified across the genome using the Illumina Infinium HumanMethylation450 array ("Illumina 450K array") (Illumina, San Diego, CA, USA). The additional 15 *DNMT3A* pathogenic variants were profiled using the Illumina Infinium EPIC array (Illumina, San Diego, CA, USA). The Bioconductor package *wateRmelon* (Pidsley et al. 2013) in R 3.4.1 (R Core Team 2017) was used to import IDAT files and, after checking for suitable sodium bisulfite conversion (bisulfite control probe median > 90%), the DNA methylation data was imported and quantile normalized using the *dasen* function in *wateRmelon* and methylation beta values produced (ratio of intensities for methylated vs

unmethylated alleles). Probes showing a detection p-value >0.05 in at least 1% of samples or a beadcount <3 in 5% of samples were removed across all samples. Any samples showing low quality, indicated by a detection p-value > 0.05 in 1% or more of probes within a sample, were removed from analysis. Probes containing common SNPs within 10 bp of the CpG site were removed (minor allele frequency $> 5\%$). Nonspecific probes and probes on the sex chromosomes were also removed (Chen et al. 2013; Price et al. 2013).

Identification of Differentially Methylated Positions

Differentially methylated positions (DMPs) were identified using a *limma* based linear model based on pathogenic variant genotype and sex as a covariate (Smyth 2004) and a Benjamini-Hochberg false discovery rate (FDR) of 5% applied (Benjamini and Hochberg 1995). When the epigenetic age was used as a covariate, a similar level of DMPs were detected (2,557 DMPs) with an 80% overlap to the *limma* model without age as a covariate. Changes in methylation were calculated based on comparison between *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers vs wildtype individuals in the Amish pedigree. The additional 15 *DNMT3A* pathogenic variants were assessed relative to 7 wild-type control samples run on the same EPIC array run. Blood cell counts were unknown and so were estimated using the DNA methylation age calculator (Horvath 2013; Koestler et al. 2013), and assessed in the linear model. To identify differentially methylated regions (DMRs), the package DMRcate was used with the same *limma* based design (Peters et al. 2015).

Gene Ontology and Functional Enrichment Analyses

Gene Ontology enrichment analysis was performed using genes annotated to FDR corrected differentially methylated positions using the *gometh* function of the *missMethyl* package

(Phipson et al. 2016) which takes into account potential bias of probe distributions on the beadchip array. KEGG pathway analysis was performed using the *gsameth* command of *missMethyl* and KEGG annotation files from the Bioconductor KEGGREST package (<http://bioconductor.org/packages/release/bioc/html/KEGGREST.html>). Regional enrichment analysis based on Illumina annotations was performed using a Chi-squared test with Yates correction in R. Differentially methylated regions were functionally annotated using the webtool GREAT (<http://great.stanford.edu/public/html/>). The top p-value ranked 1,000 DMPs were also annotated using the eFORGE tool (<https://eforge.altiusinstitute.org/>) to perform functional overlap analysis for identifying any cell or tissue specific epigenetic signals.

Quantification of Global DNA Methylation

Global DNA methylation measurements were made using the Luminometric methylation assay (LUMA) (Karimi et al. 2006) based on cleavage by a methylation sensitive restriction enzyme followed by polymerase extension assay via pyrosequencing on the Pyromark Q24 (Qiagen). Peak heights were obtained using the Pyro Q24 CpG 2.0.6 software and a *t*-test applied in R 3.4.1. Global methylation estimates from the Illumina 450k array were assessed through R 3.4.1 using summary statistics and a Wilcoxon rank sum test on two pairs of samples matched for age and sex.

DNA Methylation Age Estimation

Epigenetic age calculations were made using the DNA methylation age calculator (<https://dnamage.genetics.ucla.edu/>) for Illumina 450k data, and Illumina EPIC arrays assessed using the *agep* function of the *wateRmelon* Bioconductor package, the latter based on the original calculator developed by Steve Horvath (Horvath 2013). Accelerated age was calculated

for the Amish TBRS *DNMT3A* c.2312G>A; p.(Arg771Gln) carriers and wildtype family members, Sotos syndrome and Kabuki syndrome patients, and compared to data from 322 control individuals taken from a previous study (Hannon et al. 2016), using linear models of recorded chronological age and calculated epigenetic age. Estimates of age acceleration for the additional 15 TBRS cases were calculated by dividing the calculated epigenetic age with their chronological age. Additional NSD1 Sotos syndrome patient Illumina DNA methylation files were obtained from GEO accession GSE74432, with corresponding chronological ages derived from the associated paper (Choufani et al. 2015). KMT2D Kabuki syndrome DNA methylation data and chronological age was obtained from GEO accession GSE97362 (Butcher et al. 2017).

Validation of DMPs using Bisulfite-Pyrosequencing

Bisulfite pyrosequencing was used to validate specific differentially methylated CpG sites originally identified using the Illumina 450k array. Primers, designed using Pyromark Assay Design software (Qiagen, UK), and PCR conditions are provide in Table S7. Bisulfite conversion DNA was performed on ~500ng of DNA using the Bisulfite-Gold kit (Zymo Research, USA). PCR was performed with HOT FIREPol DNA polymerase (Solis Biodyne, Estonia) for 95°C for 15 minutes followed by 37 cycles of 95°C 15 seconds, annealing temperature (shown in Supplemental Table S7) for 15 seconds and 72°C for 30 seconds. A final extension of 72°C for 10 minutes was then applied. DNA methylation was then assessed using the resulting bisulfite PCR amplicons, together with a pyrosequencing primer on the Pyromark Q24 system (Qiagen, UK) following the manufacturer's standard instructions and the Pyro Q24 CpG 2.0.6 software.

Data Access

The raw and processed primary dataset generated in this study have been submitted to the NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE128801. R scripts are provided as Supplemental Code S1 and at the following repository: <https://github.com/arjeffries/TBRS2019>.

Acknowledgements

We are grateful to the Amish families for participating in this study, and to the Amish community for their continued support of the Windows of Hope project.

The work was supported by the Newlife Foundation for Disabled Children (Ref: SG/16-17/02, to C.G.S, A.R.J, A.H.C and E.L.B), MRC grant G1001931 (to E.L.B), MRC grant G1002279 (to A.H.C) and MRC grants MR/M008924/1 and MR/K013807/1 (to J.M).

Contributions

E.L.B. A.H.C and J.M. conceived study. R.M. and B.A.C. performed the genetic analysis. A.R.J. and R.M. performed LUMA global methylation assay. A.R.J. performed the microarray based DNA methylation analysis and all associated statistical analyses. A.R.J. and E.D. performed the pyrosequencing and associated analysis. A.R.J., C.G.S., R.M., A.H.C., J.M. and E.L.B. wrote the manuscript, H.E.C. and M.A.P., D.M., F.I.R., K.T.B., L.A., D.B., T.D., M.F.H., R.N.E., A.K., A.K., A.S., A.S., L.V.M., V.V., and N.Y. contributed samples and clinical data.

Disclosure Declaration

The authors declare that there are no conflicts of interest.

Figure Legends

Figure 1 – TBRs *DNMT3A* variants are associated with widespread DNA hypomethylation

(A) Simplified pedigree indicating the genotyping of individuals in the Amish family investigated ('+/-'; heterozygous carriers of the *DNMT3A* c.2312G>A p.(Arg771Gln) variant, '+/- Mosaic'; the *DNMT3A* c.2312G>A p.(Arg771Gln) mosaic father, and '-/-'; wildtype individuals). Black shading; individuals with a phenotype consistent with TBRs, grey shading; the father with macrocephaly and mild intellectual impairment, and white shading; unaffected individuals. Each of these samples was profiled on the Illumina 450k DNA methylation array.

(B) Volcano plot showing site-specific DNA methylation differences (x-axis) and $-\log_{10}$ P values (y-axis) from an analysis comparing Amish *DNMT3A* c.2312G>A; p.(Arg771Gln) pathogenic variant carriers and wildtype family members using the Illumina 450K array. Red values indicate the 2,606 differentially methylated positions (DMPs) detected at a Benjamini Hochberg FDR < 0.05.

(C) Top 20 Gene Ontology enrichment analysis categories associated with the 2,606 differentially methylated positions identified in *DNMT3A* c.2312G>A; p.(Arg771Gln) pathogenic variant carriers vs wildtype family members.

(D) Comparison of *DNMT3A* c.2312G>A; p.(Arg771Gln) identified differentially methylated positions (\log_2 fold change) relative to other *DNMT3A* TBRs associated variants assessed in this study (all variants grouped and measured relative to controls). Pearson correlation = 0.6620, p-value < 2.2×10^{-16} .

(E) Boxplot illustrating the DNA methylation changes observed in association with the *DNMT3A* TBRs variants studied at the differentially methylated positions identified in the Amish *DNMT3A* c.2312G>A p.(Arg771Gln) carriers. The predicted protein consequence of each *DNMT3A* variant

studied is indicated (pink; in-frame deletion, yellow; single nucleotide variant, cyan; duplications predicted to result in a frameshift, green; Amish c.2312G>A; p.(Arg771Gln) variant).

Figure 2 – Schematic representation of DNMT3A.

The positions of the disease-associated variants included in this study are indicated relative to the protein domain architecture.

Figure 3 – Altered epigenetic aging is observed in methyltransferase-associated human growth disorders.

(A) Scatter plot comparing ‘DNA methylation age’ derived from the Illumina 450K data (y-axis) and actual chronological age (x-axis) in *DNMT3A* c.2312G>A p.(Arg771Gln) pathogenic variant carriers (red) vs wildtype family members (blue). Green indicates the mosaic individual. The linear regression model is also shown.

(B) Scatter plot comparing DNA methylation age vs chronological age in patients with Sotos syndrome. Inframe legend illustrates the different *NSD1* pathogenic variants studied.

(C) Scatter plot comparing DNA methylation age vs chronological age in patients with Kabuki syndrome. Inframe legend illustrates the different *KMT2D* pathogenic variants studied.

(D) Boxplot comparing the epigenetic age acceleration rates found in association with TBRS *DNMT3A* variants, *KMT2D* Kabuki syndrome variants and *NSD1* Sotos syndrome variants. Each age acceleration observation is plotted as a circle. The dotted red line denotes no age acceleration.

References

- Benjamini Y, Hochberg Y. 1995. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B-Methodological* **57**: 289-300.
- Bjornsson HT. 2015. The Mendelian disorders of the epigenetic machinery. *Genome Res* **25**: 1473-1481.
- Breeze CE, Paul DS, van Dongen J, Butcher LM, Ambrose JC, Barrett JE, Lowe R, Rakyan VK, Iotchkova V, Frontini M et al. 2016. eFORGE: A Tool for Identifying Cell Type-Specific Signal in Epigenomic Data. *Cell Rep* **17**: 2137-2150.
- Butcher DT, Cytrynbaum C, Turinsky AL, Siu MT, Inbar-Feigenberg M, Mendoza-Londono R, Chitayat D, Walker S, Machado J, Caluseriu O et al. 2017. CHARGE and Kabuki Syndromes: Gene-Specific DNA Methylation Signatures Identify Epigenetic Mechanisms Linking These Clinically Overlapping Conditions. *Am J Hum Genet* **100**: 773-788.
- Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y et al. 2011. Dnmt3a is essential for hematopoietic stem cell differentiation. *Nat Genet* **44**: 23-31.
- Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai PC, Roetker NS, Just AC, Demerath EW, Guan W et al. 2016. DNA methylation-based measures of biological age: meta-analysis predicting time to death. *Aging (Albany NY)* **8**: 1844-1865.
- Chen T, Ueda Y, Dodge JE, Wang Z, Li E. 2003. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. *Mol Cell Biol* **23**: 5594-5605.
- Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, Gallinger S, Hudson TJ, Weksberg R. 2013. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. *Epigenetics* **8**: 203-209.

- Choufani S, Cytrynbaum C, Chung BH, Turinsky AL, Grafodatskaya D, Chen YA, Cohen AS, Dupuis L, Butcher DT, Siu MT et al. 2015. NSD1 mutations generate a genome-wide DNA methylation signature. *Nat Commun* **6**: 10207.
- Davis CA, Hitz BC, Sloan CA, Chan ET, Davidson JM, Gabdank I, Hilton JA, Jain K, Baymuradov UK, Narayanan AK et al. 2018. The Encyclopedia of DNA elements (ENCODE): data portal update. *Nucleic Acids Res* **46**: D794-D801.
- Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S et al. 2009. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. *Nat Genet* **41**: 1350-1353.
- Hannon E, Dempster E, Viana J, Burrage J, Smith AR, Macdonald R, St Clair D, Mustard C, Breen G, Therman S et al. 2016. An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation. *Genome Biol* **17**: 176.
- Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sada S, Klotzle B, Bibikova M, Fan JB, Gao Y et al. 2013. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell* **49**: 359-367.
- Heyn P, Logan CV, Fluteau A, Challis RC, Auchynnikava T, Martin CA, Marsh JA, Taglini F, Kilanowski F, Parry DA et al. 2019. Gain-of-function DNMT3A mutations cause microcephalic dwarfism and hypermethylation of Polycomb-regulated regions. *Nat Genet* **51**: 96-105.
- Hollink I, van den Ouweland AMW, Beverloo HB, Arentsen-Peters S, Zwaan CM, Wagner A. 2017. Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar DNMT3A R882 mutation. *J Med Genet* **54**: 805-808.

- Holz-Schietinger C, Matje DM, Reich NO. 2012. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. *J Biol Chem* **287**: 30941-30951.
- Horvath S. 2013. DNA methylation age of human tissues and cell types. *Genome Biol* **14**: R115.
- Horvath S, Garagnani P, Bacalini MG, Pirazzini C, Salvioli S, Gentilini D, Di Blasio AM, Giuliani C, Tung S, Vinters HV et al. 2015. Accelerated epigenetic aging in Down syndrome. *Aging Cell* **14**: 491-495.
- Horvath S, Langfelder P, Kwak S, Aaronson J, Rosinski J, Vogt TF, Eszes M, Faull RL, Curtis MA, Waldvogel HJ et al. 2016. Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. *Aging (Albany NY)* **8**: 1485-1512.
- Jeong M, Park HJ, Celik H, Ostrander EL, Reyes JM, Guzman A, Rodriguez B, Lei Y, Lee Y, Ding L et al. 2018. Loss of Dnmt3a immortalizes Hematopoietic Stem Cells In Vivo. *Cell Rep* **23**: 1-10.
- Jiang YL, Rigolet M, Bourc'his D, Nigon F, Bokesoy I, Fryns JP, Hulten M, Jonveaux P, Maraschio P, Megarbane A et al. 2005. DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. *Hum Mutat* **25**: 56-63.
- Johnson AA, Akman K, Calimport SR, Wuttke D, Stolzing A, de Magalhaes JP. 2012. The role of DNA methylation in aging, rejuvenation, and age-related disease. *Rejuvenation Res* **15**: 483-494.
- Jones PA. 2012. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat Rev Genet* **13**: 484-492.
- Karimi M, Johansson S, Ekstrom TJ. 2006. Using LUMA: a Luminometric-based assay for global DNA-methylation. *Epigenetics* **1**: 45-48.
- Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, Hammans S, Hojo K, Yamanishi H, Karpf AR, Wallace DC et al. 2011. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. *Nat Genet* **43**: 595-600.

- Koestler DC, Christensen B, Karagas MR, Marsit CJ, Langevin SM, Kelsey KT, Wiencke JK, Houseman EA. 2013. Blood-based profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis. *Epigenetics* **8**: 816-826.
- Kosaki R, Terashima H, Kubota M, Kosaki K. 2017. Acute myeloid leukemia-associated DNMT3A p.Arg882His mutation in a patient with Tatton-Brown-Rahman overgrowth syndrome as a constitutional mutation. *Am J Med Genet A* **173**: 250-253.
- Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T, Ohashi H, Naritomi K, Tsukahara M, Makita Y et al. 2002. Haploinsufficiency of NSD1 causes Sotos syndrome. *Nat Genet* **30**: 365-366.
- Leenen FA, Muller CP, Turner JD. 2016. DNA methylation: conducting the orchestra from exposure to phenotype? *Clin Epigenetics* **8**: 92.
- Lemire G, Gauthier J, Soucy JF, Delrue MA. 2017. A case of familial transmission of the newly described DNMT3A-Overgrowth Syndrome. *Am J Med Genet A* **173**:1887-1890.
- Levine ME, Lu AT, Bennett DA, Horvath S. 2015. Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer's disease related cognitive functioning. *Aging (Albany NY)* **7**: 1198-1211.
- Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. 2011. Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**: 1739-1740.
- Maierhofer A, Flunkert J, Oshima J, Martin GM, Haaf T, Horvath S. 2017. Accelerated epigenetic aging in Werner syndrome. *Aging (Albany NY)* **9**: 1143-1152.
- Marioni RE, Shah S, McRae AF, Ritchie SJ, Muniz-Terrera G, Harris SE, Gibson J, Redmond P, Cox SR, Pattie A et al. 2015. The epigenetic clock is correlated with physical and cognitive fitness in the Lothian Birth Cohort 1936. *Int J Epidemiol* **44**: 1388-1396.
- Marioni RE, Suderman M, Chen BH, Horvath S, Bandinelli S, Morris T, Beck S, Ferrucci L, Pedersen NL, Relton CL et al. 2018. Tracking the Epigenetic Clock Across the Human

- Life Course: A Meta-analysis of Longitudinal Cohort Data. *J Gerontol A Biol Sci Med Sci* **74**:57-61.
- McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G. 2010. GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol* **28**: 495-501.
- Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve HI, Beck AE, Tabor HK, Cooper GM, Mefford HC et al. 2010. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. *Nat Genet* **42**: 790-793.
- Okamoto N, Toribe Y, Shimojima K, Yamamoto T. 2016. Tatton-Brown-Rahman syndrome due to 2p23 microdeletion. *Am J Med Genet A* **170A**: 1339-1342.
- Okano M, Bell DW, Haber DA, Li E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* **99**: 247-257.
- Peters TJ, Buckley MJ, Statham AL, Pidsley R, Samaras K, R VL, Clark SJ, Molloy PL. 2015. De novo identification of differentially methylated regions in the human genome. *Epigenetics Chromatin* **8**: 6.
- Phipson B, Maksimovic J, Oshlack A. 2016. missMethyl: an R package for analyzing data from Illumina's HumanMethylation450 platform. *Bioinformatics* **32**: 286-288.
- Pidsley R, CC YW, Volta M, Lunnon K, Mill J, Schalkwyk LC. 2013. A data-driven approach to preprocessing Illumina 450K methylation array data. *BMC Genomics* **14**: 293.
- Price ME, Cotton AM, Lam LL, Farre P, Emberly E, Brown CJ, Robinson WP, Kobor MS. 2013. Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. *Epigenetics Chromatin* **6**: 4.
- Qiao Q, Li Y, Chen Z, Wang M, Reinberg D, Xu RM. 2011. The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. *J Biol Chem* **286**: 8361-8368.

- R Core Team. 2017. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
- Roadmap Epigenomics Consortium. 2015. Integrative analysis of 111 reference human epigenomes. *Nature* **518**: 317-330.
- Shen W, Heeley JM, Carlston CM, Acuna-Hidalgo R, Nillesen WM, Dent KM, Douglas GV, Levine KL, Bayrak-Toydemir P, Marcelis CL et al. 2017. The spectrum of DNMT3A variants in Tatton-Brown-Rahman syndrome overlaps with that in hematologic malignancies. *Am J Med Genet A* **173**: 3022-3028.
- Smyth GK. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol* **3**: Article3.
- Spencer DH, Russler-Germain DA, Ketkar S, Helton NM, Lamprecht TL, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Shinawi M et al. 2017. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. *Cell* **168**: 801-816 e813.
- Tatton-Brown K, Loveday C, Yost S, Clarke M, Ramsay E, Zachariou A, Elliott A, Wylie H, Ardisson A, Rittinger O et al. 2017. Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability. *Am J Hum Genet* **100**: 725-736.
- Tatton-Brown K, Seal S, Ruark E, Harmer J, Ramsay E, Del Vecchio Duarte S, Zachariou A, Hanks S, O'Brien E, Aksglaede L et al. 2014. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. *Nat Genet* **46**: 385-388.
- Tatton-Brown K, Zachariou A, Loveday C, Renwick A, Mahamdallie S, Aksglaede L, Baralle D, Barge-Schaapveld D, Blyth M, Bouma M et al. 2018. The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de novo constitutive DNMT3A variants. *Wellcome Open Res* **3**: 46.
- The Encode Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**: 57-74.

- Tlemsani C, Luscan A, Leulliot N, Bieth E, Afenjar A, Baujat G, Doco-Fenzy M, Goldenberg A, Lacombe D, Lambert L et al. 2016. SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort. *J Med Genet* **53**: 743-751.
- Wu H, Coskun V, Tao J, Xie W, Ge W, Yoshikawa K, Li E, Zhang Y, Sun YE. 2010. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. *Science* **329**: 444-448.
- Xin B, Cruz Marino T, Szekely J, Leblanc J, Cechner K, Sency V, Wensel C, Barabas M, Therriault V, Wang H. 2017. Novel DNMT3A germline mutations are associated with inherited Tatton-Brown-Rahman syndrome. *Clin Genet* **91**: 623-628.
- Zhu T, Zheng SC, Paul DS, Horvath S, Teschendorff AE. 2018. Cell and tissue type independent age-associated DNA methylation changes are not rare but common. *Aging (Albany NY)* **10**: 3541-3557.




Figure 1




Figure 2




Figure 3

ID	Mutation (nucleotide)	Mutation (protein)	Chronological Age (years)	Epigenetic Age (years)	Epigenetic Age Acceleration (fold change)	Epigenetic Age Acceleration (percentage increase)
Single nucleotide variants						
1	c.929T>A	p.(Ile310Asn)	9.27	24.2	2.61	161%
2	c.1594G>A	p.(Gly532Ser)	5.92	22.7	3.83	283%
3	c.1645T>C	p.(Cys549Arg)	9.36	25	2.67	167%
4	c.1943T>C	p.(Leu648Pro)	19.34	32.1	1.66	66%
5	c.2099C>T	p.(Pro700Leu)	13.45	32.5	2.42	142%
6	c.2245C>T	p.(Arg749Cys)	13.87	19.6	1.41	41%
7	c.2246G>A	p.(Arg749His)	8.9	33.6	3.78	278%
8	c.2312G>A	p.(Arg771Gln)	8 - 23	15.8 - 36.1	1.41	41%*
9	c.2512A>G	p.(Asn838Asp)	14.44	38.8	2.69	169%
10	c.2644C>T	p.(Arg882Cys)	2.28	21.9	9.61	861%
11	c.2705T>C	p.(Phe902Ser)	9.84	25.4	2.58	158%
12	c.2711C>T	p.(Pro904Leu)	7.78	35.7	4.59	359%
In-frame deletions						
13	c.889_891delTGG	p.(Trp297del)	5.82	23.2	3.99	299%
14	c.2255_2257delTCT	p.(Phe752del)	3.05	10.6	3.48	248%
Duplications resulting in a frameshift						
15	c.2297dupA	p.(Arg767fs)	3.12	14.4	4.62	362%
16	c.934_937dupTCTT	p.(Ser312fs)	21	38.9	1.85	85%

Table 1 – TBRS *DNMT3A* variants are associated with epigenetic age acceleration.

DNMT3A genotype (p.(Arg771Gln), shown in blue; p.(Arg882Cys), shown in red), chronological age, predicted epigenetic age and percentage of age acceleration calculated for TBRS syndrome cases included in this study, * Epigenetic age acceleration taken from the linear regression model applied to 4 individuals carrying the mutation.



Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging

Aaron Richard Jeffries, Reza Maroofian, Claire G Salter, et al.

Genome Res. published online June 3, 2019

Access the most recent version at doi:[10.1101/gr.243584.118](https://doi.org/10.1101/gr.243584.118)

Supplemental Material <http://genome.cshlp.org/content/suppl/2019/06/27/gr.243584.118.DC1>

P<P Published online June 3, 2019 in advance of the print journal.

Accepted Manuscript Peer-reviewed and accepted for publication but not copyedited or typeset; accepted manuscript is likely to differ from the final, published version.

Open Access Freely available online through the *Genome Research* Open Access option.

Creative Commons License This manuscript is Open Access. This article, published in *Genome Research*, is available under a Creative Commons License (Attribution 4.0 International license), as described at <http://creativecommons.org/licenses/by/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

A banner for a webinar. On the left, the word "Webinar" is in white on a dark blue background. To its right, the text "Automation-friendly full-length scRNA-seq" is in white on a lighter blue background. On the far right, there is a green circular logo with the text "that's GOOD science" and the Takara logo.

The Takara logo, featuring a stylized "T" in a circle followed by the word "Takara" in blue. Below it, in smaller text, are "Genetech", "Taka", and "celartis".

To subscribe to *Genome Research* go to:
<http://genome.cshlp.org/subscriptions>
